Table 2.
Type of neoadjuvant treatment
| Characteristic | N = 165a |
|---|---|
| Chemotherapy | 151 (91.5%) |
| Endocrine therapy | 24 (14.5%) |
| Immunotherapy (including anti-HER2) | 42 (25.4%) |
an (%)
HER2 Human epidermal growth factor receptor 2
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.